Mary Anne Dellva
Overview
Explore the profile of Mary Anne Dellva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piras de Oliveira C, Dellva M, Bue-Valleskey J, Chang A, Liao B
J Diabetes Complications
. 2023 Nov;
38(1):108648.
PMID: 38035641
Aims: To investigate contributions of changes in fasting plasma glucose (FPG) and postprandial glucose (PPG) to changes in hemoglobin A1c (HbA1c) and time-in-range (TIR, 70-180 mg/dL) in people with type...
2.
Leohr J, Dellva M, LaBell E, Coutant D, Arrubla J, Plum-Morschel L, et al.
Diabetes Obes Metab
. 2023 Oct;
26(1):215-223.
PMID: 37814517
Aims: To compare the time to hyperglycaemia recovery after ultra rapid lispro (URLi; Lyumjev®) versus Humalog in a randomized, double-blind crossover study. Materials And Methods: Thirty-two adults with type 1...
3.
Wadwa R, Laffel L, Franco D, Dellva M, Knights A, Pollom R
Diabetes Obes Metab
. 2022 Sep;
25(1):89-97.
PMID: 36054737
Aims: To evaluate the efficacy and safety of ultra-rapid lispro (URLi) versus lispro in a paediatric population with type 1 diabetes (T1D) in a Phase 3, treat-to-target study. Materials And...
4.
Leohr J, Dellva M, LaBell E, Coutant D, Linnebjerg H
Clin Ther
. 2022 May;
44(6):836-847.
PMID: 35577602
Purpose: Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This study compared the pharmacokinetic profile...
5.
Leohr J, Kazda C, Liu R, Reddy S, Dellva M, Matzopoulos M, et al.
Diabetes Obes Metab
. 2021 Oct;
24(2):187-195.
PMID: 34605142
Aims: To compare the pharmacokinetics (PK), glucodynamics (GD) and tolerability following single and multiple daily subcutaneous doses of ultra rapid lispro (URLi) and Humalog® in patients with type 2 diabetes...
6.
Kazda C, Leohr J, Liu R, Reddy S, Dellva M, Loh M, et al.
Diabetes Obes Metab
. 2021 Oct;
24(2):196-203.
PMID: 34595812
Aim: To compare the pharmacokinetics (PK), glucodynamics (GD), and tolerability following single and multiple daily subcutaneous (SC) doses of ultra rapid lispro (URLi) and Humalog® in patients with type 1...
7.
Leohr J, Dellva M, Carter K, LaBell E, Linnebjerg H
Clin Pharmacokinet
. 2021 May;
60(11):1423-1434.
PMID: 34041713
Background And Objective: Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This pooled analysis compared...
8.
Bue-Valleskey J, Klaff L, Cho J, Dellva M, Schloot N, Tobian J, et al.
Diabetes Ther
. 2021 Jan;
12(2):569-580.
PMID: 33458803
Introduction: The PRONTO-T1D study, which evaluated the efficacy and safety of ultra rapid lispro (URLi) versus lispro in adults with type 1 diabetes (T1D), met the primary endpoint of noninferiority...
9.
Leohr J, Dellva M, LaBell E, Coutant D, Klein O, Plum-Moerschel L, et al.
Clin Ther
. 2020 Sep;
42(9):1762-1777.e4.
PMID: 32900535
Purpose: Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This study compared the pharmacokinetic and...
10.
Linnebjerg H, LaBell E, Dellva M, Coutant D, Leohr J
Diabetes Ther
. 2020 Jun;
11(8):1709-1720.
PMID: 32535742
Introduction: Ultra rapid lispro (URLi) is a novel insulin lispro formulation that was developed to more closely match physiological insulin secretion. The aims of this study were to demonstrate the...